Results 271 to 280 of about 27,891 (313)

evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer’s disease

Alzheimer's Research & Therapy
Disease-modifying therapies targeting the diverse pathophysiology of Alzheimer’s disease (AD), including neuroinflammation, represent potentially important and novel approaches. The glucagon-like peptide-1 receptor agonist semaglutide is approved for the
Jeffrey L. Cummings, A. Atri, Howard H. Feldman, Oskar Hansson, Mary Sano, Filip K. Knop, P. Johannsen, Teresa Léon, P. Scheltens   +8 more
semanticscholar   +1 more source

Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.

New England Journal of Medicine
BACKGROUND Semaglutide at a dose of 2.4 mg has established weight-loss and cardiovascular benefits, and cagrilintide at a dose of 2.4 mg has shown promising results in early-phase trials; the efficacy of the combination (known as CagriSema) on weight ...
W. T. Garvey, Matthias Blüher, Cynthia Karenina Osorto Contreras, Melanie J. Davies, Eva Winning Lehmann, Kirsi H. Pietiläinen, D. Rubino, Paolo Sbraccia, T. Wadden, N. Zeuthen, J. P. Wilding   +10 more
semanticscholar   +1 more source

Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial.

The Lancet
BACKGROUND Peripheral artery disease is a highly morbid type of atherosclerotic vascular disease involving the legs and is estimated to affect over 230 million individuals globally.
M. Bonaca, A. Catarig, K. Houlind, B. Ludvik, J. Nordanstig, C. Ramesh, N. Rasouli, H. Sourij, Alex Videmark, Subodh Verma   +9 more
semanticscholar   +1 more source

Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes.

New England Journal of Medicine
BACKGROUND Obesity and type 2 diabetes are prevalent in patients with heart failure with preserved ejection fraction and are characterized by a high symptom burden.
M. Kosiborod, Mark C. Petrie, B. Borlaug, J. Butler, M. Davies, G. Hovingh, D. Kitzman, D. V. Møller, M. Treppendahl, Subodh Verma, T. J. Jensen, Karoline Liisberg, Marie L Lindegaard, W. Abhayaratna, Fozia Z. Ahmed, Tuvia Ben‐Gal, V. Chopra, Justin A. Ezekowitz, Michael Fu, Hiroshi Ito, Małgorzata Lelonek, V. Melenovský, Béla Merkely, Julio Núñez, E. Perna, Morten Schou, M. Senni, Kavita Sharma, P. van der Meer, Dirk von Lewinski, Dennis Wolf, Sanjiv J. Shah   +31 more
semanticscholar   +1 more source

Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.

New England Journal of Medicine
BACKGROUND Cagrilintide and semaglutide have each been shown to induce weight loss as monotherapies. Data are needed on the coadministration of cagrilintide and semaglutide (called CagriSema) for weight management in adults with type 2 diabetes ...
Melanie J. Davies, H. Bajaj, C. Broholm, A. Eliasen, W. T. Garvey, C. L. le Roux, I. Lingvay, Christian Bøge Lyndgaard, Julio Rosenstock, Sue D Pedersen   +9 more
semanticscholar   +1 more source

Subcutaneous weekly semaglutide with automated insulin delivery in type 1 diabetes: a double-blind, randomized, crossover trial

Nature Medicine
Efforts to improve glycemic control in type 1 diabetes are ongoing. We performed a randomized, double-blind, crossover trial to assess semaglutide as adjunct to automated insulin delivery therapy in adults with type 1 diabetes.
Melissa-Rosina Pasqua, Michael A. Tsoukas, A. Kobayati, Wedyan M Aboznadah, A. Jafar, Ahmad Haidar   +5 more
semanticscholar   +1 more source

Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity

JAMA Internal Medicine
Key Points Question How does weight loss differ between patients receiving tirzepatide compared with semaglutide among a clinical population of adults with overweight or obesity?
Patricia J. Rodriguez, Brianna M. Goodwin Cartwright, S. Gratzl, R. Brar, Charlotte Baker, Ty J. Gluckman, N. Stucky   +6 more
semanticscholar   +1 more source

Semaglutid

pharma-kritik, 2019
Semaglutid ist ein weiterer GLP-1-Rezeptoragonist, der nur einmal wöchentlich injiziert werden muss und wie z.B. Liraglutid makrovaskuläre Komplikationen reduziert. Das Nutzen/Risiko-Verhältnis einer chronischen Verabreichung ist noch nicht definitiv geklärt.
openaire   +1 more source

Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide.

JAMA ophthalmology
Importance Anecdotal experience raised the possibility that semaglutide, a glucagon-like peptide 1 receptor agonist (GLP-1 RA) with rapidly increasing use, is associated with nonarteritic anterior ischemic optic neuropathy (NAION).
Jimena Tatiana Hathaway, Madhura P. Shah, David B. Hathaway, S. Zekavat, Drenushe Krasniqi, J. Gittinger, Dean M. Cestari, Robert Mallery, Bardia Abbasi, Marc A. Bouffard, B. Chwalisz, Tais Estrela, Joseph F Rizzo   +12 more
semanticscholar   +1 more source

Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis.

New England Journal of Medicine
BACKGROUND Weight reduction has been shown to alleviate symptoms of osteoarthritis of the knee, including pain. The effect of glucagon-like peptide-1 receptor agonists on outcomes in knee osteoarthritis among persons with obesity has not been well ...
H. Bliddal, Harold E. Bays, S. Czernichow, Joanna Uddén Hemmingsson, J. Hjelmesæth, Thomas Hoffmann Morville, Anna Koroleva, Jesper Skov Neergaard, Patricia Vélez Sánchez, Sean Wharton, Alicja Wizert, L. E. Kristensen   +11 more
semanticscholar   +1 more source